Help your patients learn about their kidney stones
The following patient education materials are available for you to download and share with your patients so that they can understand why kidney stones develop, how they are treated, and what they can do to avoid getting them in the future.
various types of stones, common obstruction sites, and recurrence.
Kidney Stones Educational
Familiarize your patients with the many different
types of kidney stones.
ABCs of Kidney Stones
The objective of this patient brochure is to set forth simple and practical guidelines that your patients can use to minimize their chances of developing another stone.
Available in English and Spanish
StoneDisease.org offers patients and physicians informational tools and resources to help prevent kidney stones and guide treatment.
INDICATIONS: Urocit®-K (potassium citrate) is indicated for the management of renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones.
Important Safety Information
- With hyperkalemia or in conditions associated with hyperkalemia, such as chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical activity in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown
- For whom there might be delayed tablet passage through the GI tract, e.g., gastric stasis, esophageal compression, intestinal obstruction or stricture
- With peptic ulcer disease
- With active urinary tract infection
- With renal insufficiency (GFR < 0.7 ml/kg/min)
WARNINGS AND PRECAUTIONS:
- Hyperkalemia: In patients with impaired mechanisms for excreting potassium, Urocit-K administration can produce hyperkalemia (which can develop rapidly and may be asymptomatic) and cardiac arrest. The use of Urocit-K in any condition that impairs potassium excretion (e.g., chronic renal failure, severe myocardial damage, heart failure) should be avoided. Concomitant administration of Urocit-K with potassium-sparing diuretics should also be avoided since simultaneous administration can result in severe hyperkalemia.
- Gastrointestinal lesions: If there is severe vomiting, abdominal pain, or gastrointestinal bleeding, Urocit-K should be discontinued immediately and the possibility of bowel perforation or obstruction investigated. Drugs that slow gastrointestinal transit (e.g., anticholinergics) may increase the gastrointestinal irritation produced by potassium salts.
ADVERSE REACTIONS: Adverse reactions associated with Urocit-K include minor gastrointestinal complaints such as gastrointestinal discomfort, vomiting, diarrhea, loose bowel movements, or nausea. These may be alleviated by taking the dose with meals or snacks or reducing the dosage.